企业信息
17
  • 入驻时间: 2008-08-20
  • 联系人:客户经理
  • 电话:400-968-7988
  • 联系时,请说明易展网看到的
  • Email:fuwu@bioleaf.com
产品详情
  • 产品名称:MC1568,ClassIIaHDACInhibitor

  • 产品型号:M60224-2s
  • 产品厂商:其它品牌
  • 产品价格:79
  • 折扣价格:0
  • 产品文档:
你添加了1件商品 查看购物车
简单介绍:
MC1568,ClassIIaHDACInhibitor
详情介绍:
Product Information
Molecular Weight: 314.31
Formula: C17H15FN2O3
Purity: ≥98%
CAS#: 852475-26-4
Solubility: DMSO up to 100 mM
Chemical Name: 3-[5-(3-(3-Fluorophenyl)-3-oxopropen-1-yl)-1-methyl-1H-pyrrol-2-yl]-N-hydroxy-2-propenamide
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

MC1568 is a potent and selective inhibitor of class IIa histone deacetylases (HDACs), with IC50 of 100 nM for maize HD1-A. It is 34-fold more selective for HD1-A than HD1-B, 176-fold more selective for class I HDACs. It exhibits tissue-selective inhibition between members of class II deacetylases in vivo; inhibits HDAC4 and HDAC5 in skeletal muscle and the heart without affecting HDAC3 activity. It arrests myogenesis through the stabilization of myocyte enhancer factor 2D (MEF2D)-HDAC3/4 complex. In a recent study of pancreatic explants, MC1568 enhances expression of Pax4, a key factor required for proper β-and δ-cell differentiation and amplifies endocrine β- and δ-cells.


How to Use:

In vitro:  MC1568 was used at 5-10µM final concentration in vitro and cellular assays.

In vivo: MC1568 could be orally dosed to mice at 50 mg/kg once per day (formulation: 0.5% CMC, 5 mg/mL). It has an apparent tissue-selective HDAC inhibition. In skeletal muscle and heart, MC1568 inhibits the activity of HDAC4 and HDAC5 without affecting HDAC3 activity, thereby leaving MEF2-HDAC complexes in a repressed state.


Reference: 

  • 1.    Mai A, et al. Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. (2005) J Med Chem. 48(9):3344-53.
  • 2.      Mai A, et al. Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia. (2007) Mol Pharmacol.72(5):1111-23.
  • 3.      Duong V, et al. Specific activity of class II histone deacetylases in human breast cancer cells.(2008) Mol Cancer Res.6(12):1908-19.
  • 4.      Nebbioso A, et al. Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. (2009) EMBO Rep. 10(7):776-82.
  • 5.    Lenoir O, et al. Specific control of pancreatic endocrine β- and δ-cell mass by class IIa histone deacetylases HDAC4, HDAC5, and HDAC9. (2011) Diabetes. 60(11):2861-71.


    
    


Products are for research use only. Not for human use.

标题:
内容:
联系人:
联系电话:
Email:
公司名称:
联系地址:
 
 
注:1.可以使用快捷键Alt+S或Ctrl+Enter发送信息!
2.如有必要,请您留下您的详细联系方式!
相关文章

沪公网安备 31011202007337号